AlphaMark Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History

AlphaMark Advisors’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-20	Closed	–	–	479
2016 Q3	$0	Hold	20	–	–	﹤0.01%	352
2016 Q2	$1K	Hold	20	–	–	﹤0.01%	328
2016 Q1	$1K	Hold	20	–	–	﹤0.01%	312
2015 Q4	$1K	Hold	20	–	–	﹤0.01%	302
2015 Q3	$1K	Hold	20	–	–	﹤0.01%	288
2015 Q2	$1K	Hold	20	–	–	﹤0.01%	293
2015 Q1	$1K	Buy	+20	New	+$796	﹤0.01%	296

Other funds holding IPXL

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AlphaMark Advisors's IPXL Position: Q4 2016 in Review

AlphaMark Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q4 2016, closing a stake of 20 shares.

AlphaMark Advisors first reported a position in IPXL in Q1 2015 and held it in 7 quarters. The position peaked at $1K in Q2 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

AlphaMark Advisors reported no remaining Impax Laboratories, Inc. position as of Q4 2016 after selling out during the quarter.
AlphaMark Advisors sold 20 Impax Laboratories, Inc. shares in Q4 2016.
AlphaMark Advisors first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 7 quarters.
AlphaMark Advisors's Impax Laboratories, Inc. position peaked at $1K in Q2 2016.
198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on AlphaMark Advisors's 13F filing for Q4 2016, filed 26 Jan 2017.